A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Zoledronic Acid (Reclast)

Bisphosphonate class · 15 generic manufacturers · 24 ANDAs filed at FDA.

First FDA approval2007-04-01
Generic availableYes · 15 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$612,954 in CY2024 Part D spend6K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.465/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.465
Across all dosage forms in distribution.
Highest NADAC
$0.465
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Zoledronic Acid used for?

Zoledronic Acid is a Bisphosphonate medication tracked in Medicare Part D.

Is there a generic for Zoledronic Acid?

Yes. 24 ANDAs filed at FDA, 15 generic manufacturers currently shipping.

How much does my plan pay for Zoledronic Acid?

Across 329 Part D plans, Zoledronic Acid averages $0.465/unit (NADAC). Lowest available: $0.465/unit. Highest in distribution: $0.465/unit.

Is Zoledronic Acid on the FDA shortage list?

No. Zoledronic Acid is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Bisphosphonate2 alternatives in D1
01
Alendronate
Brand: Alendronate
$0.121Lowest NADAC
8Generic mfrs
$119.3MCY24 Part D spend
Compare →
02
Ibandronate
Bisphosphonate
$2.79Lowest NADAC
9Generic mfrs
$39.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.